KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D ...
Apr 20, 2026
0
5









